The bill directs OCI to award grants in an amount of up to $500,000 in each fiscal year to health care providers to develop and implement a patient pharmacy benefits tool that would allow prescribers to disclose the cost of prescription drugs for patients. The tool must be usable by physicians and other prescribers to determine the cost of prescription drugs for their patients. Any health care provider that receives a grant to develop and implement a patient pharmacy benefits tool is required to contribute matching funds equal to at least 50 percent of the total grant awarded.
Prescription drug purchasing entity study
The bill requires OCI to conduct a study on the viability of creating or implementing a state prescription drug purchasing entity.
Licensure of pharmacy services administrative organizations
The bill requires that a pharmacy services administrative organization (PSAO) be licensed by OCI. Under the bill, a PSAO is an entity operating in Wisconsin that does all of the following:
1. Contracts with an independent pharmacy to conduct business on the pharmacy’s behalf with a third-party payer.
2. Provides at least one administrative service to an independent pharmacy and negotiates and enters into a contract with a third-party payer or pharmacy benefit manager on the pharmacy’s behalf.
The bill defines “independent pharmacy” to mean a licensed pharmacy operating in Wisconsin that is under common ownership with no more than two other pharmacies. “Administrative service” is defined to mean assisting with claims or audits, providing centralized payment, performing certification in a specialized care program, providing compliance support, setting flat fees for generic drugs, assisting with store layout, managing inventory, providing marketing support, providing management and analysis of payment and drug dispensing data, or providing resources for retail cash cards. The bill defines “third-party payer” to mean an entity operating in Wisconsin that pays or insures health, medical, or prescription drug expenses on behalf of beneficiaries. The bill uses the current law definition of “pharmacy benefit manager,” which is an entity doing business in Wisconsin that contracts to administer or manage prescription drug benefits on behalf of an insurer or other entity that provides prescription drug benefits to Wisconsin residents.
To obtain the license required by the bill, a person must apply to OCI and provide the contact information for the applicant and a contact person, evidence of financial responsibility of at least $1,000,000, and any other information required by the commissioner by rule. Under the bill, the license fee is set by the commissioner, and the term of a license is two years.
The bill also requires that a PSAO disclose to OCI the extent of any ownership or control by an entity that provides pharmacy services; provides prescription drug or device services; or manufactures, sells, or distributes prescription drugs, biologicals, or medical devices. The PSAO must notify OCI within five days of any material change in its ownership or control related to such an entity.
Licensure of pharmaceutical representatives
The bill requires a pharmaceutical representative to be licensed by OCI and to display the pharmaceutical representative’s license during each visit with a health care professional. The bill defines “pharmaceutical representative” to mean an individual who markets or promotes pharmaceuticals to health care professionals on behalf of a pharmaceutical manufacturer for compensation.
The term of a license issued under the bill is one year, and the license is renewable. The application to obtain or renew a license must include the applicant’s contact information, a description of the type of work in which the applicant will engage, the license fee, an attestation that professional education requirements are met, proof that any penalties and other fees are paid, and any other information required by OCI by rule. Under the bill, the license fee is set by the commissioner. The bill requires the pharmaceutical representative to report, within four business days, any change to the information provided on the application or any material change to the pharmaceutical representative’s business operations or other information required to be reported under the bill.
The bill requires that a pharmaceutical representative complete a professional education course prior to becoming licensed and to annually complete at least five hours of continuing professional education courses. The coursework must include, at a minimum, training in ethical standards, whistleblower protections, and the laws and rules applicable to pharmaceutical marketing. The bill directs the commissioner to regularly publish a list of courses that fulfill the education requirements. Under the bill, a course provider must disclose any conflict of interest to the commissioner, and the courses may not be provided by the employer of a pharmaceutical representative or be funded by the pharmaceutical industry or a third party funded by the industry.
The bill requires that, no later than June 1 of each year, a pharmaceutical representative report to OCI the pharmaceutical representative’s total number of contacts with health care professionals in Wisconsin, the specialties of those health care professionals, the location and duration of each contact, the pharmaceuticals discussed, and the value of any item provided to a health care professional. The bill directs the commissioner to publish the information on OCI’s website without identifying individual health care professionals.
The bill requires that a pharmaceutical representative, during each contact with a health care professional, disclose the wholesale acquisition cost of any pharmaceuticals discussed and the names of at least three generic prescription drugs from the same therapeutic class.
The bill directs the commissioner to promulgate ethical standards for pharmaceutical representatives. Additionally, the bill prohibits a pharmaceutical representative from engaging in deceptive or misleading marketing of a pharmaceutical product; using a title or designation that could reasonably lead a licensed health care professional, or an employee or representative of such a professional, to believe that the pharmaceutical representative is licensed to practice in a health occupation unless the pharmaceutical representative holds a license to practice in that health occupation; or attending a patient examination without the patient’s consent.
An individual who violates any of the requirements under the bill is subject to a forfeiture, and the individual’s license may be suspended or revoked. An individual whose license is revoked must wait at least two years before applying for a new license.
Insulin safety net programs
The bill requires insulin manufacturers to establish a program under which qualifying Wisconsin residents who are in urgent need of insulin and are uninsured or have limited insurance coverage can be dispensed insulin at a pharmacy. An individual is in urgent need of insulin if the individual needs insulin in order to avoid the likelihood of suffering a significant health consequence and possesses less than a seven-day supply of insulin readily available for use. Under the program, if a qualifying individual in urgent need of insulin provides a pharmacy with a form attesting that the individual meets the program’s eligibility requirements, specified proof of residency, and a valid insulin prescription, the pharmacy must dispense a 30-day supply of insulin to the individual and may charge the individual a copayment of no more than $35. The pharmacy may submit an electronic payment claim for the insulin’s acquisition cost to the manufacturer or agree to receive a replacement of the same insulin in the amount dispensed.
The bill also requires that each insulin manufacturer establish a patient assistance program to make insulin available to any qualifying Wisconsin resident who, among other requirements, is uninsured or has limited insurance coverage and whose family income does not exceed 400 percent of the federal poverty line. Under the bill, an individual must apply to participate in a manufacturer’s program. If the manufacturer determines that the individual meets the program’s eligibility requirements, the manufacturer must issue the individual a statement of eligibility, which is valid for 12 months and may be renewed. Under the bill, if an individual with a statement of eligibility and valid insulin prescription requests insulin from a pharmacy, the pharmacy must submit an order to the manufacturer, who must then provide a 90-day supply of insulin at no charge to the individual or pharmacy. The pharmacy may charge the individual a copayment of no more than $50. Under the bill, a manufacturer is not required to issue a statement of eligibility if the individual has prescription drug coverage through an individual or group health plan and the manufacturer determines that the individual’s insulin needs are better addressed through the manufacturer’s copayment assistance program. In such case, the manufacturer must provide the individual with necessary drug coupons to submit to a pharmacy, and the individual may not be required to pay more than a $50 copayment for a 90-day supply of insulin.
Under the bill, if the manufacturer determines that an individual is not eligible for the patient assistance program, the individual may file an appeal with OCI. The bill directs OCI to establish procedures for deciding appeals. Under the bill, OCI must issue a decision within 10 days, and that decision is final.
The bill requires that insulin manufacturers annually report to OCI certain information, including the number of individuals served and the cost of insulin dispensed under the programs and that OCI annually report to the governor and the legislature on the programs. The bill also directs OCI to conduct public outreach and develop an information sheet about the programs, conduct satisfaction surveys of individuals and pharmacies that participate in the programs, and report to the governor and the legislature on the surveys by July 1, 2028. Additionally, the bill requires that OCI develop a training program for health care navigators to assist individuals in accessing appropriate long-term insulin options and maintain a list of trained navigators.
The bill provides that a manufacturer that fails to comply with the bill’s provisions may be assessed a forfeiture of up to $200,000 per month of noncompliance, which increases to $400,000 per month if the manufacturer continues to be in noncompliance after six months and to $600,000 per month if the manufacturer continues to be in noncompliance after one year. The bill’s requirements do not apply to manufacturers with annual insulin sales revenue in Wisconsin of no more than $2,000,000 or to insulin that costs less than a specified dollar amount.
Prescription Drug Affordability Review Board
The bill creates a Prescription Drug Affordability Review Board, whose purpose is to protect Wisconsin residents and other stakeholders from the high costs of prescription drugs. The board consists of the commissioner of insurance and the following members, all of whom are appointed by the governor for four-year terms:
1. Two members who represent the pharmaceutical drug industry, at least one of whom is a licensed pharmacist.
2. Two members who represent the health insurance industry.
3. Two members who represent the health care industry, at least one of whom is a licensed practitioner.
4. Two members who represent the interests of the public.
The bill requires the board to meet in open session at least four times per year to review prescription drug pricing information. The board must provide at least two weeks’ public notice of each meeting, make the meeting’s materials publicly available at least one week prior to the meeting, and provide the opportunity for public comment. The bill imposes conflict of interest requirements for the board relating to recusal and public disclosure of certain conflicts. The bill directs the board to access and assess drug pricing information, to the extent practicable, by accessing and assessing information from other states, by assessing spending for the drug in Wisconsin, and by accessing other available pricing information.
Under the bill, the board must conduct drug cost affordability reviews. The board must identify prescription drugs whose launch wholesale acquisition cost exceeds specified thresholds, prescription drugs whose increase in wholesale acquisition cost exceeds specified thresholds, and other prescription drugs that may create affordability challenges for the health care system in Wisconsin. For each identified prescription drug, the board must determine whether to conduct an affordability review by seeking stakeholder input and considering the average patient cost share for the drug. During an affordability review, the board must determine whether use of the prescription drug that is fully consistent with the labeling approved by the federal Food and Drug Administration or standard medical practice has led or will lead to an affordability challenge for the health care system in Wisconsin. In making this determination, the bill requires the board to consider a variety of factors, which include the following:
1. The drug’s wholesale acquisition cost.
2. The average monetary price concession, discount, or rebate the manufacturer provides, or is expected to provide, for the drug to health plans.
3. The total amount of price concessions, discounts, and rebates the manufacturer provides to each pharmacy benefit manager for the drug.
4. The price at which therapeutic alternatives have been sold and the average monetary concession, discount, or rebate the manufacturer provides, or is expected to provide, to health plan payors and pharmacy benefit managers for therapeutic alternatives.
5. The costs to health plans based on patient access consistent with federal labeled indications and recognized standard medical practice.
6. The impact on patient access resulting from the drug’s cost relative to insurance benefit design.
7. The current or expected dollar value of drug-specific patient access programs that are supported by the manufacturer.
8. The relative financial impacts to health, medical, or social services costs that can be quantified and compared to baseline effects of existing therapeutic alternatives.
9. The average patient copay or other cost sharing for the drug.
If the board determines that a prescription drug will lead to an affordability challenge, the bill directs the board to establish an upper payment limit for that drug that applies to all purchases and payor reimbursements of the drug dispensed or administered to individuals in Wisconsin. In establishing the upper payment limit, the board must consider the cost of administering the drug, the cost of delivering it to consumers, and other relevant administrative costs. For certain drugs, the board must solicit information from the manufacturer regarding the price increase and, if the board determines that the price increase is not a result of the need for increased manufacturing capacity or other effort to improve patient access during a public health emergency, the board must establish an upper payment limit equal to the drug’s cost prior to the price increase.
Further, this bill provides $500,000 in program revenue in fiscal year 2026–27 for onetime implementation costs associated with establishing an Office of Prescription Drug Affordability in OCI. The bill provides that the Office of Prescription Drug Affordability is responsible for prescription drug affordability programming within OCI and for overseeing the operations of the Prescription Drug Affordability Review Board. Additionally, the bill authorizes and funds for fiscal year 2026–27 16.0 positions for the Office of Prescription Drug Affordability.
Finally, the bill credits to the appropriation account for OCI’s general program operations all moneys received from the regulation of pharmacy benefit managers, pharmacy benefit management brokers, pharmacy benefit management consultants, pharmacy services administrative organizations, and pharmaceutical sales representatives.
This proposal may contain a health insurance mandate requiring a social and financial impact report under s. 601.423, stats.
For further information see the state fiscal estimate, which will be printed as an appendix to this bill.
The people of the state of Wisconsin, represented in senate and assembly, do enact as follows:
SB50,1
1Section 1. 15.07 (3) (bm) 7. of the statutes is created to read: SB50,2,3215.07 (3) (bm) 7. The prescription drug affordability review board shall meet 3at least 4 times each year. SB50,24Section 2. 15.735 of the statutes is created to read: SB50,2,7515.735 Same; attached board. (1) There is created a prescription drug 6affordability review board attached to the office of the commissioner of insurance 7under s. 15.03. The board shall consist of the following members: SB50,2,88(a) The commissioner of insurance or his or her designee. SB50,3,39(b) Two members appointed for 4-year terms who represent the
1pharmaceutical drug industry, including pharmaceutical drug manufacturers and 2wholesalers. At least one of the members appointed under this paragraph shall be 3a pharmacist licensed in this state. SB50,3,54(c) Two members appointed for 4-year terms who represent the health 5insurance industry, including insurers and pharmacy benefit managers. SB50,3,96(d) Two members appointed for 4-year terms who represent the health care 7industry, including hospitals, physicians, pharmacies, and pharmacists. At least 8one of the members appointed under this paragraph shall be a licensed health care 9practitioner. SB50,3,1110(e) Two members appointed for 4-year terms who represent the interests of 11the public. SB50,3,1412(2) A member appointed under sub. (1), except for a member appointed under 13sub. (1) (b), may not be an employee of, a board member of, or a consultant to a drug 14manufacturer or trade association for drug manufacturers. SB50,3,1915(3) Any conflict of interest, including any financial or personal association, 16that has the potential to bias or has the appearance of biasing an individual’s 17decision in matters related to the board or the conduct of the board’s activities shall 18be considered and disclosed when appointing that individual to the board under 19sub. (1). SB50,320Section 3. 20.005 (3) (schedule) of the statutes: at the appropriate place, 21insert the following amounts for the purposes indicated: SB50,45Section 4. 20.145 (1) (a) of the statutes is created to read: SB50,4,7620.145 (1) (a) State operations. The amounts in the schedule for general 7program operations. SB50,58Section 5. 20.145 (1) (g) 4. of the statutes is created to read: SB50,4,12920.145 (1) (g) 4. All moneys received from the regulation of pharmacy benefit 10managers, pharmacy benefit management brokers, pharmacy benefit management 11consultants, pharmacy services administrative organizations, and pharmaceutical 12sales representatives. SB50,613Section 6. 49.45 (18) (ac) of the statutes is amended to read: SB50,5,21449.45 (18) (ac) Except as provided in pars. (am) to (d), and subject to par. (ag), 15any person eligible for medical assistance under s. 49.46, 49.468, or 49.47, or for the 16benefits under s. 49.46 (2) (a) and (b) under s. 49.471, shall pay up to the maximum 17amounts allowable under 42 CFR 447.53 to 447.58 for purchases of services 18provided under s. 49.46 (2). The service provider shall collect the specified or 19allowable copayment, coinsurance, or deductible, unless the service provider 20determines that the cost of collecting the copayment, coinsurance, or deductible 21exceeds the amount to be collected. The department shall reduce payments to each 22provider by the amount of the specified or allowable copayment, coinsurance, or 23deductible. No provider may deny care or services because the recipient is unable to
1share costs, but an inability to share costs specified in this subsection does not 2relieve the recipient of liability for these costs. SB50,73Section 7. 49.45 (18) (ag) of the statutes is repealed. SB50,84Section 8. 49.45 (18) (b) 8. of the statutes is created to read: SB50,5,5549.45 (18) (b) 8. Prescription drugs. SB50,96Section 9. 255.056 (2g) of the statutes is created to read: SB50,5,127255.056 (2g) The department may partner with out-of-state drug repository 8programs. The department may authorize a medical facility or pharmacy that 9elects to participate in the drug repository program to receive drugs or supplies 10from out of state, and the department may authorize an out-of-state entity that 11participates in a partner out-of-state drug repository program to receive drugs or 12supplies from Wisconsin. SB50,1013Section 10. 450.085 (3) of the statutes is created to read: SB50,5,1614450.085 (3) An applicant for renewal of a license under s. 450.08 (2) (a) may 15count, for purposes of the continuing education requirement under sub. (1), up to 10 16hours spent as a volunteer at a free and charitable clinic approved by the board. SB50,1117Section 11. 601.31 (1) (nv) of the statutes is created to read: SB50,5,1918601.31 (1) (nv) For issuing or renewing a license as a pharmaceutical 19representative under s. 601.56, an amount to be set by the commissioner by rule. SB50,1220Section 12. 601.31 (1) (nw) of the statutes is created to read: SB50,5,2321601.31 (1) (nw) For issuing or renewing a license as a pharmacy services 22administrative organization under s. 601.57, an amount to be set by the 23commissioner by rule. SB50,13
1Section 13. 601.41 (14) of the statutes is created to read: SB50,6,72601.41 (14) Value-based diabetes medication pilot project. The 3commissioner shall develop a pilot project to direct a pharmacy benefit manager, as 4defined in s. 632.865 (1) (c), and a pharmaceutical manufacturer to create a value-5based, sole-source arrangement to reduce the costs of prescription medication used 6to treat diabetes. The commissioner may promulgate rules to implement this 7subsection. SB50,148Section 14. 601.415 (14) of the statutes is created to read: SB50,6,149601.415 (14) Patient pharmacy benefits tool. (a) From the appropriation 10under s. 20.145 (1) (a), beginning in the 2026-27 fiscal year, the office shall award 11grants in a total amount of up to $500,000 each fiscal year to health care providers 12to develop and implement a tool for prescribers to disclose the cost of prescription 13drugs for patients. The tool must be usable by physicians and other prescribers to 14determine the cost of prescription drugs for their patients. SB50,6,1715(b) Any health care provider that receives a grant under par. (a) shall 16contribute matching funds equal to at least 50 percent of the grant amount 17awarded. SB50,1518Section 15. 601.56 of the statutes is created to read: SB50,6,2019601.56 Pharmaceutical representatives. (1) Definitions. In this 20section: SB50,6,2321(a) “Health care professional” means a physician or other health care 22practitioner who is licensed to provide health care services or to prescribe 23pharmaceutical or biologic products. SB50,7,2
1(b) “Pharmaceutical” means a medication that may legally be dispensed only 2with a valid prescription from a health care professional. SB50,7,53(c) “Pharmaceutical representative” means an individual who markets or 4promotes pharmaceuticals to health care professionals on behalf of a 5pharmaceutical manufacturer for compensation.